Search

Displaying results 5131 - 5140 of 5925 in total
  1. Drug

    4-Methoxyamphetamine

    go.drugbank.com/drugs/DB01472
    ExperimentalIllicit

    Synonyms: D,L-p-methoxyamphetamine, P-methoxyamfetamineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  2. Drug

    Calanolide A

    go.drugbank.com/drugs/DB04886
    Investigational

    Calanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity. Both drugs are being developed by Sarawak...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Bicifadine

    go.drugbank.com/drugs/DB04889
    Investigational

    Bicifadine (DOV-220075) is a nonopioid analgesic. It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile. Bicifadine was shown to have potent analgesic activity in vivo...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  4. Drug

    Becocalcidiol

    go.drugbank.com/drugs/DB04891
    Investigational

    Becocalcidiol is a vitamin D(3) analogue which has not caused hypercalcaemia or significant irritation in preclinical trials.

    Categories: Vitamin D and Analogues
  5. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. ...

    Categories: P-glycoprotein inhibitors
  6. Drug

    Taberminogene vadenovec

    go.drugbank.com/drugs/DB05011
    Experimental

    Taberminogene vadenovec (EG004) is a novel product consisting of a local delivery device and a gene-based medicine, being developed to prevent the blocking of veins and arteries that frequently occurs after vascular surgery. The initial ...

  7. Drug

    SQ-109

    go.drugbank.com/drugs/DB05186
    Investigational

    SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten th...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  8. Drug

    Palovarotene

    go.drugbank.com/drugs/DB05467
    Approved

    Fibrodysplasia Ossificans Progressiva (FOP), with an estimated worldwide prevalence of one in 2 million individuals, is an exceptionally rare genetic disorder. FOP is caused by a gain-of-function mutation in the ACVR1/ALK2 gene which res...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Inducers
  9. Drug

    Telaprevir

    go.drugbank.com/drugs/DB05521
    ApprovedWithdrawn

    Telaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  10. Drug

    DDP-225

    go.drugbank.com/drugs/DB05642
    Investigational

    The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered compound represents a novel approach to treating IBS-d and other functional GI diseases.